Search

Your search keyword '"Vieni, A"' showing total 584 results
Start Over Author "Vieni, A"
584 results on '"Vieni, A"'

2. A case report of disseminated blastomycosis presenting as a renal mass

Author

Casey Vieni, Bobbi S. Pritt, and Loren Herrera Hernandez

Subjects
Blastomycosis, Genitourinary, Kidney mass, Blastomyces dermatitidis, Pathology, RB1-214
Abstract

Blastomycosis, caused by dimorphic fungi from the genus Blastomyces, is an endemic disease of the midwestern United States that typically presents as pulmonary disease mimicking community acquired pneumonia. Extrapulmonary blastomycosis occurs in up to 50% of cases and most commonly involves the skin. Genitourinary blastomycosis is a rare entity most often seen in disseminated systemic blastomycosis, and rarely as the presenting manifestation of blastomycosis. Here we describe a case report of a 78-year-old Midwestern man incidentally found to have a large kidney mass and multiple pulmonary nodules. Renal biopsy revealed multiple sites of granulomatous inflammation and budding yeast consistent with Blastomyces species. We present the patient’s clinical history, treatment regimen, and clinical course.

Published
2024
Full Text
View/download PDF

3. BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?

Author

Daniele Fanale, Lidia Rita Corsini, Chiara Brando, Ugo Randazzo, Marco Bono, Erika Pedone, Alessandro Perez, Roberta Sciacchitano, Daniela Cancelliere, Paola Piraino, Ambra Giurintano, Tancredi Didier Bazan Russo, Pietro Ferraro, Gaetana Rinaldi, Valeria Spinnato, Vincenzo Gennusa, Gianfranco Pernice, Salvatore Vieni, Gianni Pantuso, Antonio Russo, and Viviana Bazan

Subjects
BRCA1, BRCA2, germline pathogenic variants, HBOC, male breast cancer, melanoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

IntroductionAlthough hereditary male neoplasms are quite rare, individuals harbouring germline BRCA1/2 pathogenic variants (PVs) may have a risk of developing tumours associated with Hereditary Breast and Ovarian Cancer (HBOC) syndrome, including male breast (MBC), prostate (PCa) and pancreatic (PC) cancers, and melanoma. Women and men showed a comparable genetic architecture of cancer susceptibility, but there are some gender-specific features. Since little is known about cancer genetic susceptibility in male population, our study was aimed at investigating the frequency of BRCA1/2 PVs in men with HBOC syndrome-associated tumors, in order to understand whether differences in gender may reflect in the prevalence and spectrum of germline alterations.Patients and methodsWe retrospectively collected and analysed clinical information of 352 HBOC-associated male cancer patients genetically tested for germline BRCA1/2 PVs by Next-Generation Sequencing analysis, enrolled, from February 2018 to January 2024, at the “Regional Center for the prevention, diagnosis and treatment of rare and heredo-familial tumors of adults” of the University-Hospital Policlinico “P. Giaccone” of Palermo (Italy).ResultsOur investigation revealed that 7.4% of patients was carrier of a germline BRCA PV, with an almost total prevalence of BRCA2 alterations. In particular, 65.4% of BRCA-positive patients developed MBC, 19.2% had PC, 11.6% developed PCa, and only 3.8% had melanoma. Specifically, MBC individuals showed a BRCA-associated genetic predisposition in 17% of cases, whereas patients with PCa or PC exhibited a lower frequency of BRCA2 PVs, taking into account the current national criteria for access to germline genetic testing.DiscussionOur study showed a high heterogeneity in prevalence of germline BRCA2 PVs among men which could reflect a potential gender-specific genetic heterogeneity. Therefore, BRCA-associated male tumours could be due to BRCA2 PVs different from those usually detected in women. In the event that it is demonstrated, in future, that male cancers are genetically distinct entities from those female this could improve personalized risk evaluation and guide therapeutic choices for patients of both sexes, in order to obtain a gender equality in cancer care.

Published
2024
Full Text
View/download PDF

4. The 'Octopus Head' Dermoglandular Flap: A Novel Technique for Breast Tissue Rearranging after Implant Removal

Author

Matteo Rossi, MD, PhD, Emanuele Cammarata, MD, Calogero Cipolla, MD, PhD, Salvatore Vieni, MD, PhD, Francesca Toia, MD, PhD, and Adriana Cordova, MD

Subjects
Surgery, RD1-811
Abstract

Background:. Patients with previous breast augmentation may need implant removal for mechanical complications or other causes. After prosthesis removal, the residual parenchyma can be reshaped through a mastopexy with rearrangement of breast tissue. Several techniques have been described in the literature, but none of them can be considered the gold standard. In this study, we present our preliminary experience in breast tissue rearranging after implant removal through a novel technique: the “octopus head” dermoglandular flap. Methods:. From January 2019 to October 2022, nine patients (18 breasts) underwent implant removal and simultaneous breast remodeling with the tissue obtained from the dermoglandular excess of the breast and shaped like an octopus head. Patient’s demographic and clinical characteristics, postoperative complications, and patient-reported satisfaction were recorded. Results:. Mean age was 46.7 years. Body mass index ranged between 22.5 and 27.6 kg per m2. The majority of patients had moderate ptosis (67%). Breast implants were removed due to bilateral capsular contracture (n = 3), unilateral implant rupture with contralateral capsular contracture (n = 2), bilateral implant rupture (n = 3), and unilateral periprosthetic seroma (n = 1). We observed two minor complications: one postoperative hemorrhage with subsequent hematoma that was managed conservatively, and one nipple–areola complex malposition that underwent revision surgery. All patients were satisfied with the aesthetic and functional result. Conclusions:. The octopus head dermoglandular flap has proved to be a safe and reliable option for breast tissue rearranging after implant removal, providing a good and stable cosmetic result, a low complication rate, and high patient-reported satisfaction.

Published
2024
Full Text
View/download PDF

6. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer

Author

Fanale, Daniele, Brando, Chiara, Corsini, Lidia Rita, Cutaia, Sofia, Di Donna, Mariano Catello, Randazzo, Ugo, Filorizzo, Clarissa, Lisanti, Chiara, Magrin, Luigi, Gurrera, Vittorio, Romano, Raffaella, Dimino, Alessandra, Bazan Russo, Tancredi Didier, Olive, Daniel, Vieni, Salvatore, Pantuso, Gianni, Giordano, Antonio, Chiantera, Vito, Russo, Antonio, Bazan, Viviana, and Iovanna, Juan Lucio

Published
2023
Full Text
View/download PDF

14. Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Imaging Protocols

Author

Einstein, A.J., Pascual, T.N.B., Paez, D., Dondi, M., Better, N., Bouyoucef, S.E., Karthikeyan, G., Kashyap, R., Lele, V., Magboo, V.P.C., Mahmarian, J.J., Meeks, J.B., Mercuri, M., Mut, F., Rehani, M.M., Vitola, J.V., Alexanderson, E., Allam, A., Al-Mallah, M.H., Bom, H., Flotats, A., Jerome, S., Kaufmann, P.A., Luxenburg, O., Mahmarian, J., Shaw, L.J., Underwood, S.R., Vitola, J., Amouri, W., Essabbah, H., Gassama, S.S., Makhdomi, K.B., El Mustapha, G.I.E., El Ouchdi, N., Qaïs, N., Soni, N., Vangu, W., Abazid, R.M., Adams, B., Agarwal, V., Alfeeli, M.A., Alnafisi, N., Bernabe, L., Bural, G.G., Chaiwatanarat, T., Chandraguptha, J.M., Cheon, G.J., Cho, I., Dogan, A.S., Eftekhari, M., Frenkel, A., Garty, I., George, S., Geramifar, P., Golan, H., Habib, S., Hussain, R., Im, H., Jeon, H.-J., Kalawat, T., Kang, W.J., Keng, F., Klaipetch, A., Kumar, P.G., Lee, J., Lee, W.W., Lim, I., Macaisa, C.M.M., Malhotra, G., Mittal, B.R., Mohammad, M.H., Mohan, P., Mulyanto, I.D., Nariman, D., Nayak, U.N., Niaz, K., Nikolov, G., Obaldo, J.M., Ozturk, E., Park, J.M., Park, S., Patel, C.D., Phuong, H.K., Quinon, A.P., Rajini, T.R., Saengsuda, Y., Santiago, J., Sayman, H.B., Shinto, A.S., Sivasubramaniyan, V., Son, M.H., Sudhakar, P., Syed, G.M.S., Tamaki, N., Thamnirat, K., Thientunyakit, T., Thongmak, S., Velasco, D.N., Verma, A., Vutrapongwatana, U., Wang, Y., Won, K.S., Yao, Z., Yingsa-nga, T., Yudistiro, R., Yue, K.T., Zafrir, N., Adrian, S.C., Agostini, D., Aguadé, S., Armitage, G., Backlund, M., Backman, M., Baker, M., Balducci, M.T., Bavelaar, C., Berovic, M., Bertagna, F., Beuchel, R., Biggi, A., Bisi, G., Bonini, R., Bradley, A., Brudin, L., Bruno, I., Busnardo, E., Casoni, R., Choudhri, A., Cittanti, C., Clauss, R., Costa, D.C., Costa, M., Dixon, K., Dziuk, M., Egelic, N., Eriksson, I., Fagioli, G., de Faria, D.B., Florimonte, L., Francini, A., French, M., Gallagher, E., Garai, I., Geatti, O., Genovesi, D., Gianolli, L., Gimelli, A., Giudice, E. del, Halliwell, S., Hansson, M.J., Harrison, C., Homans, F., Horton, F., Jędrzejuk, D., Jogi, J., Johansen, A., Johansson, H., Kalnina, M., Kaminek, M., Kiss, A., Kobylecka, M., Kostkiewicz, M., Kropp, J., Kullenberg, R., Lahoutte, T., Lang, O., Larsson, Y.H., Lázár, M., Leccisotti, L., Leners, N., Lindner, O., Lipp, R.W., Maenhout, A., Maffioli, L., Marcassa, C., Martins, B., Marzullo, P., Medolago, G., Mendiguchía, C.G., Mirzaei, S., Mori, M., Nardi, B., Nazarenko, S., Nikoletic, K., Oleksa, R., Parviainen, T., Patrina, J., Peace, R., Pirich, C., Piwowarska-Bilska, H., Popa, S., Prakash, V., Pubul, V., Puklavec, L., Rac, S., Ratniece, M., Rogan, S.A., Romeo, A., Rossi, M., Ruiz, D., Sabharwal, N., Salobir, B.G., Santos, A.I., Saranovic, S., Sarkozi, A., Schneider, R.P., Sciagra, R., Scotti, S., Servini, Z., Setti, L.R., Starck, S.-Å., Vajauskas, D., Veselý, J., Vieni, A., Vignati, A., Vito, I.M., Weiss, K., Wild, D., Zdraveska-Kochovska, M., Agüro, R.N., Alvarado, N., Barral, C.M., Beretta, M., Berrocal, I., Cuellar, J.F. Batista, Cabral Chang, T.-M., Cabrera Rodríguez, L.O., Canessa, J., Castro Mora, G., Claudia, A.C., Clavelo, G.F., Júnior, A.F. Cruz, Faccio, F.F., Fernández, K.M., Garibo, J.R. Gomez, Gonzalez, U., González E, P., Guzzo, M.A., Jofre, J., Kapitán, M., Kempfer, G., Lopez, J.L., Massardo V, T., Medeiros Colaco, I., Mesquita, C.T., Montecinos, M., Neubauer, S., Pabon, L.M., Puente, A., Rochela Vazquez, L.M., Serna Macias, J.A., Silva Pino, A.G., Huber, F.Z. Tártari, Tovar, A.P., Vargas, L., Wiefels, C., Aljizeeri, A., Alvarez, R.J., Barger, D., Beardwood, W., Behrens, J., Brann, L., Brown, D., Carr, H., Churchwell, K., Comingore, G.A., Corbett, J., Costello, M., Cruz, F., Depinet, T., Dorbala, S., Earles, M., Esteves, F.P., Etherton, E., Fanning, R.J., Jr., Fornace, J., Franks, L., Gewirtz, H., Gulanchyn, K., Hannah, C.-L., Hays, J., Hendrickson, J., Hester, J., Holmes, K., Johnson, A., Jopek, C., Lewin, H., Lyons, J., Manley, C., Meden, J., Moore, S., Moore, W.H., Murthy, V., Nace, R., Neely, D., Nelson, L., Niedermaier, O., Rice, D., Rigs, R., Schiffer, K., Schockling, E., Schultz, T., Schumacker, T., Sheesley, B., Sheikh, A., Siegel, B., Slim, A.M., Smith, J., Szulc, M., Tanskersley, N., Tilkemeier, P., Valdez, G.D., Vrooman, R., Wawrowicz, D., Winchester, D.E., Alcheikh, A., Allen, B., Atkins, E., Bevan, J., Bonomini, C., Christiansen, J., Clack, L., Craig, E., Dixson, H., Duncan, I., Fredericks, S., Gales, S., Hampson, R., Hanley, T., Hartcher, K., Hassall, J., Kelley, B., Kelly, S., Kidd, T., de Kort, T., Larcos, G., Macdonald, W., McGrath, C., Murdoch, E., O'Malley, S., O'Rourke, M., Pack, M., Pearce, R., Praehofer, R., Ramsay, S., Scarlett, L., Smidt, K., Souvannavong, F., Taubman, K., Taylor, G., Tse, K., Unger, S., Weale, J., Hirschfeld, Cole B., Mercuri, Mathew, Pascual, Thomas N.B., Karthikeyan, Ganesan, Vitola, João V., Mahmarian, John J., Better, Nathan, Bouyoucef, Salah E., Hee-Seung Bom, Henry, Lele, Vikram, Magboo, V. Peter C., Alexánderson, Erick, Allam, Adel H., Al-Mallah, Mouaz H., Dorbala, Sharmila, Flotats, Albert, Jerome, Scott, Kaufmann, Philipp A., Luxenburg, Osnat, Shaw, Leslee J., Underwood, S. Richard, Rehani, Madan M., Paez, Diana, Dondi, Maurizio, and Einstein, Andrew J.

Published
2021
Full Text
View/download PDF

15. Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer

Author

Calogero Cipolla, Antonio Galvano, Salvatore Vieni, Federica Saputo, Simona Lupo, Mario Latteri, Giuseppa Graceffa, and Maria Rosaria Valerio

Subjects
Breast cancer, Axillary staging, Sentinel lymph node biopsy, Optimal number, False-negative rate, Survival, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Sentinel lymph node biopsy is the gold standard surgical technique for axillary staging in patients with clinically node-negative. However, it is still uncertain what is the optimal number of sentinel lymph nodes (SLNs) to be removed to reduce the false-negative rate. The aim of this study was to investigate whether patients with a single negative SLN have a worse prognosis than those with two or more negative SLNs. Methods A retrospective review was conducted on a large series of SLN-negative breast cancer patients. Survival outcomes and regional recurrence rate were evaluated according to the number of removed SLNs. Secondly, the contribution of different adjuvant therapies on disease-free survival was explored. Statistical analysis included the chi-square, Wilcoxon–Mann–Whitney test, and Kaplan–Meier survival analysis. Results A total of 1080 patients were included in the study. A first group consisted of 328 patients in whom a single SLN was retrieved, and a second group consisted of 752 patients in whom two or more SLNs were retrieved. There was no relevant difference in median DFS (64.9 vs 41.4) for SLN = 1 vs SLN > 1 groups (HR 0.76, CI 95% 0.39–1.46; p = 0.38). A statistically significant difference in mDFS was showed only for HT-treated patients who were SLN = 1 if compared to SLN > 1 (100.6 months versus 35.3 months). Conclusions There is likely a relationship between the number of resected SNL and mDFS. Our results, however, showed no relevant difference in median DFS for SLN = 1 vs SLN > 1 group, except for a subset of the patients treated with hormone therapy.

Published
2021
Full Text
View/download PDF

16. Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery

Author

Simone Di Franco, Paola Bianca, Davide Stefano Sardina, Alice Turdo, Miriam Gaggianesi, Veronica Veschi, Annalisa Nicotra, Laura Rosa Mangiapane, Melania Lo Iacono, Irene Pillitteri, Sander van Hooff, Federica Martorana, Gianmarco Motta, Eliana Gulotta, Vincenzo Luca Lentini, Emanuele Martorana, Micol Eleonora Fiori, Salvatore Vieni, Maria Rita Bongiorno, Giorgio Giannone, Dario Giuffrida, Lorenzo Memeo, Lorenzo Colarossi, Marzia Mare, Paolo Vigneri, Matilde Todaro, Ruggero De Maria, Jan Paul Medema, and Giorgio Stassi

Subjects
Science
Abstract

Obesity is a major risk factor for cancer related death. Here, the authors show that visceral adipose-derived factors promote vasculogenesis and metastatic dissemination by activation of STAT3, which inhibits miR-200a and enhances ZEB2 expression, effectively reprogramming colorectal cancer cells into a highly metastatic phenotype.

Published
2021
Full Text
View/download PDF

17. Worldwide Diagnostic Reference Levels for Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging: Findings From INCAPS

Author

Einstein, A.J., Pascual, T.N.B., Paez, D., Dondi, M., Better, N., Bouyoucef, S.E., Karthikeyan, G., Kashyap, R., Lele, V., Magboo, V.P.C., Mahmarian, J.J., Meeks, J.B., Mercuri, M., Mut, F., Rehani, M.M., Vitola, J.V., Alexanderson, E., Allam, A., Al-Mallah, M.H., Bom, H., Flotats, A., Jerome, S., Kaufmann, P.A., Luxenburg, O., Mahmarian, J., Shaw, L.J., Underwood, S.R., Vitola, J., Amouri, W., Essabbah, H., Gassama, S.S., Makhdomi, K.B., El Mustapha, G.I.E., El Ouchdi, N., Qaïs, N., Soni, N., Vangu, W., Abazid, R.M., Adams, B., Agarwal, V., Alfeeli, M.A., Alnafisi, N., Bernabe, L., Bural, G.G., Chaiwatanarat, T., Chandraguptha, J.M., Cheon, G.J., Cho, I., Dogan, A.S., Eftekhari, M., Frenkel, A., Garty, I., George, S., Geramifar, P., Golan, H., Habib, S., Hussain, R., Im, H., Jeon, H.-J., Kalawat, T., Kang, W.J., Keng, F., Klaipetch, A., Kumar, P.G., Lee, J., Lee, W.W., Lim, I., Macaisa, C.M.M., Malhotra, G., Mittal, B.R., Mohammad, M.H., Mohan, P., Mulyanto, I.D., Nariman, D., Nayak, U.N., Niaz, K., Nikolov, G., Obaldo, J.M., Ozturk, E., Park, J.M., Park, S., Patel, C.D., Phuong, H.K., Quinon, A.P., Rajini, T.R., Saengsuda, Y., Santiago, J., Sayman, H.B., Shinto, A.S., Sivasubramaniyan, V., Son, M.H., Sudhakar, P., Syed, G.M.S., Tamaki, N., Thamnirat, K., Thientunyakit, T., Thongmak, S., Velasco, D.N., Verma, A., Vutrapongwatana, U., Wang, Y., Won, K.S., Yao, Z., Yingsa-nga, T., Yudistiro, R., Yue, K.T., Zafrir, N., Adrian, S.C., Agostini, D., Aguadé, S., Armitage, G., Backlund, M., Backman, M., Baker, M., Balducci, M.T., Bavelaar, C., Berovic, M., Bertagna, F., Beuchel, R., Biggi, A., Bisi, G., Bonini, R., Bradley, A., Brudin, L., Bruno, I., Busnardo, E., Casoni, R., Choudhri, A., Cittanti, C., Clauss, R., Costa, D.C., Costa, M., Dixon, K., Dziuk, M., Egelic, N., Eriksson, I., Fagioli, G., de Faria, D.B., Florimonte, L., Francini, A., French, M., Gallagher, E., Garai, I., Geatti, O., Genovesi, D., Gianolli, L., Gimelli, A., del Giudice, E., Halliwell, S., Hansson, M.J., Harrison, C., Homans, F., Horton, F., Jędrzejuk, D., Jogi, J., Johansen, A., Johansson, H., Kalnina, M., Kaminek, M., Kiss, A., Kobylecka, M., Kostkiewicz, M., Kropp, J., Kullenberg, R., Lahoutte, T., Lang, O., Larsson, Y.H., Lázár, M., Leccisotti, L., Leners, N., Lindner, O., Lipp, R.W., Maenhout, A., Maffioli, L., Marcassa, C., Martins, B., Marzullo, P., Medolago, G., Mendiguchía, C.G., Mirzaei, S., Mori, M., Nardi, B., Nazarenko, S., Nikoletic, K., Oleksa, R., Parviainen, T., Patrina, J., Peace, R., Pirich, C., Piwowarska-Bilska, H., Popa, S., Prakash, V., Pubul, V., Puklavec, L., Rac, S., Ratniece, M., Rogan, S.A., Romeo, A., Rossi, M., Ruiz, D., Sabharwal, N., Salobir, B.G., Santos, A.I., Saranovic, S., Sarkozi, A., Schneider, R.P., Sciagra, R., Scotti, S., Servini, Z., Setti, L.R., Starck, S.-Å., Vajauskas, D., Veselý, J., Vieni, A., Vignati, A., Vito, I.M., Weiss, K., Wild, D., Zdraveska-Kochovska, M., Agüro, R.N., Alvarado, N., Barral, C.M., Beretta, M., Berrocal, I., Cuellar, J.F. Batista, Chang, T-M. Cabral, Rodríguez, L.O. Cabrera, Canessa, J., Mora, G. Castro, Claudia, A.C., Clavelo, G.F., Júnior, A.F. Cruz, Faccio, F.F., Fernández, K.M., Garibo, J.R. Gomez, Gonzalez, U., González E, P., Guzzo, M.A., Jofre, J., Kapitán, M., Kempfer, G., Lopez, J.L., Massardo V, T., Colaco, I. Medeiros, Mesquita, C.T., Montecinos, M., Neubauer, S., Pabon, L.M., Puente, A., Vazquez, L.M. Rochela, Macias, J.A. Serna, Pino, A.G. Silva, Huber, F.Z. Tártari, Tovar, A.P., Vargas, L., Wiefels, C., Aljizeeri, A., Alvarez, R.J., Barger, D., Beardwood, W., Behrens, J., Brann, L., Brown, D., Carr, H., Churchwell, K., Comingore, G.A., Corbett, J., Costello, M., Cruz, F., Depinet, T., Dorbala, S., Earles, M., Esteves, F.P., Etherton, E., Fanning, R.J., Jr., Fornace, J., Franks, L., Gewirtz, H., Gulanchyn, K., Hannah, C.-L., Hays, J., Hendrickson, J., Hester, J., Holmes, K., Johnson, A., Jopek, C., Lewin, H., Lyons, J., Manley, C., Meden, J., Moore, S., Moore, W.H., Murthy, V., Nace, R., Neely, D., Nelson, L., Niedermaier, O., Rice, D., Rigs, R., Schiffer, K., Schockling, E., Schultz, T., Schumacker, T., Sheesley, B., Sheikh, A., Siegel, B., Slim, A.M., Smith, J., Szulc, M., Tanskersley, N., Tilkemeier, P., Valdez, G.D., Vrooman, R., Wawrowicz, D., Winchester, D.E., Alcheikh, A., Allen, B., Atkins, E., Bevan, J., Bonomini, C., Christiansen, J., Clack, L., Craig, E., Dixson, H., Duncan, I., Fredericks, S., Gales, S., Hampson, R., Hanley, T., Hartcher, K., Hassall, J., Kelley, B., Kelly, S., Kidd, T., de Kort, T., Larcos, G., Macdonald, W., McGrath, C., Murdoch, E., O'Malley, S., O'Rourke, M., Pack, M., Pearce, R., Praehofer, R., Ramsay, S., Scarlett, L., Smidt, K., Souvannavong, F., Taubman, K., Taylor, G., Tse, K., Unger, S., Weale, J., Hirschfeld, Cole B., Dondi, Maurizio, Pascual, Thomas N.B., Mercuri, Mathew, Vitola, Joao, Karthikeyan, Ganesan, Better, Nathan, Mahmarian, John J., Bouyoucef, Salah E., Hee-Seung Bom, Henry, Lele, Vikram, Magboo, Vincent Peter C., Alexánderson, Erick, Allam, Adel H., Al-Mallah, Mouaz H., Flotats, Albert, Jerome, Scott, Kaufmann, Philipp A., Luxenburg, Osnat, Underwood, S. Richard, Rehani, Madan M., Vassileva, Jenia, Paez, Diana, and Einstein, Andrew J.

Published
2021
Full Text
View/download PDF

18. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

Author

Daniele Fanale, Lidia Rita Corsini, Chiara Brando, Sofia Cutaia, Mariano Catello Di Donna, Clarissa Filorizzo, Maria Chiara Lisanti, Ugo Randazzo, Luigi Magrin, Raffaella Romano, Tancredi Didier Bazan Russo, Daniel Olive, Salvatore Vieni, Gianni Pantuso, Vito Chiantera, Antonio Russo, Viviana Bazan, and Juan Lucio Iovanna

Subjects
BTLA, butyrophilins, serum CA125, circulating immune checkpoints, HGSOC, PD-1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The most common subtype of ovarian cancer (OC) is the high-grade serous ovarian carcinoma (HGSOC), accounting for 70%–80% of all OC deaths. Although HGSOC is a potentially immunogenic tumor, clinical studies assessing the effectiveness of inhibitors of programmed death protein and its ligand (PD-1/PD-L1) in OC patients so far showed only response rates 401 U/ml and each soluble protein above respective concentration cutoff were covariates associated with shorter PFS (

Published
2022
Full Text
View/download PDF

19. The diagnostic accuracy of mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis

Author

Antonio Galvano, Luisa Castellana, Valerio Gristina, Maria La Mantia, Lavinia Insalaco, Nadia Barraco, Alessandro Perez, Sofia Cutaia, Valentina Calò, Tancredi Didier Bazan Russo, Edoardo Francini, Lorena Incorvaia, Mario Giuseppe Mirisola, Salvatore Vieni, Christian Rolfo, Viviana Bazan, and Antonio Russo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: The circulating tumor DNA (ctDNA) diagnostic accuracy for detecting phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA ) mutations in breast cancer (BC) is under discussion. We aimed to compare plasma and tissue PIK3CA alterations, encompassing factors that could affect the results. Methods: Two reviewers selected studies from different databases until December 2020. We considered BC patients with matched tumor tissue and plasma ctDNA. We performed meta-regression and subgroup analyses to explore sources of heterogeneity concerning tumor burden, diagnostic technique, sample size, sampling time, biological subtype, and hotspot mutation. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the related area under the curve (AUC) were elaborated for the overall population and each subgroup. Results: The pooled analysis was carried out on 25 cohorts for a total of 1966 patients. The overall ctDNA sensitivity and specificity were 0.73 (95% CI: 0.70–0.77) and 0.87 (95% CI: 0.85–0.89). The AUC was 0.93. Pooled concordance, negative predictive value and positive predictive value values were 0.87 (95% CI: 0.82–0.92), 0.86 (95% CI: 0.81–0.90), and 0.89 (95% CI: 0.81–0.95) with pooled PLR, NLR, and DOR of 7.94 (95% CI: 4.90–12.86), 0.33 (95% CI: 0.25–0.45), and 33.41 (95% CI: 17.23–64.79), respectively. The pooled results consistently favored next-generation sequencing (NGS)- over polymerase chain reaction-based methodologies. The best ctDNA performance in terms of sensitivity, specificity, and AUC (0.85, 0.99, and 0.94, respectively) was observed in the low-time sampling subgroup (⩽18 days between tissue and plasma collection). Meta-regression and subgroup analyses highlighted sampling time as a possible major cause of heterogeneity. Conclusions: These findings reliably estimate the high ctDNA accuracy for the detection of PIK3CA mutations. A ctDNA-first approach for the assessment of PIK3CA mutational status by NGS may accurately replace tissue tumor sampling, representing the preferable strategy at diagnosis of metastatic BC in patients who present with visceral involvement and at least two metastatic lesions, primarily given low clinical compliance or inaccessible metastatic sites.

Published
2022
Full Text
View/download PDF

23. An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics

Author

Viviana Benfante, Alessandro Stefano, Muhammad Ali, Riccardo Laudicella, Walter Arancio, Antonino Cucchiara, Fabio Caruso, Francesco Paolo Cammarata, Claudia Coronnello, Giorgio Russo, Monica Miele, Alessandra Vieni, Antonino Tuttolomondo, Anthony Yezzi, and Albert Comelli

Subjects
in vitro test, radiopharmaceuticals radiobiology, gamma counter, radiotheranostics, imaging, cancer, Medicine (General), R5-920
Abstract

Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ) radiation through radiation decay. Therefore, they are used in the biomedical field to label biomolecules or drugs for diagnostic imaging applications, such as positron emission tomography (PET) and/or single-photon emission computed tomography (SPECT). A growing field of research is the development of new radiopharmaceuticals for use in cancer treatments. Preclinical studies are the gold standard for translational research. Specifically, in vitro radiopharmaceutical studies are based on the use of radiopharmaceuticals directly on cells. To date, radiometric β- and γ-counters are the only tools able to assess a preclinical in vitro assay with the aim of estimating uptake, retention, and release parameters, including time- and dose-dependent cytotoxicity and kinetic parameters. This review has been designed for researchers, such as biologists and biotechnologists, who would like to approach the radiobiology field and conduct in vitro assays for cellular radioactivity evaluations using radiometric counters. To demonstrate the importance of in vitro radiopharmaceutical assays using radiometric counters with a view to radiogenomics, many studies based on 64Cu-, 68Ga-, 125I-, and 99mTc-labeled radiopharmaceuticals have been revised and summarized in this manuscript.

Published
2023
Full Text
View/download PDF

26. BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?

Author

Fanale, Daniele, Corsini, Lidia Rita, Brando, Chiara, Randazzo, Ugo, Bono, Marco, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Cancelliere, Daniela, Piraino, Paola, Giurintano, Ambra, Bazan Russo, Tancredi Didier, Ferraro, Pietro, Rinaldi, Gaetana, Spinnato, Valeria, Gennusa, Vincenzo, Pernice, Gianfranco, Vieni, Salvatore, Pantuso, Gianni, and Russo, Antonio

Subjects
HEREDITARY cancer syndromes, GERM cells, CANCER susceptibility, GENETIC testing, MALE breast cancer, BREAST cancer
Abstract

Introduction: Although hereditary male neoplasms are quite rare, individuals harbouring germline BRCA1/2 pathogenic variants (PVs) may have a risk of developing tumours associated with Hereditary Breast and Ovarian Cancer (HBOC) syndrome, including male breast (MBC), prostate (PCa) and pancreatic (PC) cancers, and melanoma. Women and men showed a comparable genetic architecture of cancer susceptibility, but there are some gender-specific features. Since little is known about cancer genetic susceptibility in male population, our study was aimed at investigating the frequency of BRCA1/2 PVs in men with HBOC syndrome-associated tumors, in order to understand whether differences in gender may reflect in the prevalence and spectrum of germline alterations. Patients and methods: We retrospectively collected and analysed clinical information of 352 HBOC-associated male cancer patients genetically tested for germline BRCA1/2 PVs by Next-Generation Sequencing analysis, enrolled, from February 2018 to January 2024, at the "Regional Center for the prevention, diagnosis and treatment of rare and heredo-familial tumors of adults" of the University-Hospital Policlinico "P. Giaccone" of Palermo (Italy). Results: Our investigation revealed that 7.4% of patients was carrier of a germline BRCA PV, with an almost total prevalence of BRCA2 alterations. In particular, 65.4% of BRCA-positive patients developed MBC, 19.2% had PC, 11.6% developed PCa, and only 3.8% had melanoma. Specifically, MBC individuals showed a BRCA-associated genetic predisposition in 17% of cases, whereas patients with PCa or PC exhibited a lower frequency of BRCA2 PVs, taking into account the current national criteria for access to germline genetic testing. Discussion: Our study showed a high heterogeneity in prevalence of germline BRCA2 PVs among men which could reflect a potential gender-specific genetic heterogeneity. Therefore, BRCA-associated male tumours could be due to BRCA2 PVs different from those usually detected in women. In the event that it is demonstrated, in future, that male cancers are genetically distinct entities from those female this could improve personalized risk evaluation and guide therapeutic choices for patients of both sexes, in order to obtain a gender equality in cancer care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Association between Hashimoto’s thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients

Author

Giuseppa Graceffa, Renato Patrone, Salvatore Vieni, Silvia Campanella, Sergio Calamia, Iole Laise, Giovanni Conzo, Mario Latteri, and Calogero Cipolla

Subjects
Hashimoto’s thyroiditis, Papillary thyroid carcinoma, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Abstract Background The association between Hashimoto’s thyroiditis (HT) and papillary thyroid carcinoma (PTC) is a controversial question that is still under debate, its pathological significance and the eventual clinical implications of this association remaining unclear. Methods The data regarding 305 patients were retrospectively analyzed. The patients were divided in two different groups. A first group made up of 142 patients undergoing surgery for differentiated thyroid carcinoma was compared to a control group of 142 analogous subjects operated for normofunctioning goiter. A second group was made up of 163 patients who had undergone total thyroidectomy (TT) with pre-operative diagnosis of HT. Results In the first group of patients an association with HT was found in 28,6% of the patients with final histopathological diagnosis of PTC versus 7,7% of the patients with histopathological diagnosis of multinodular goiter, which was a significant difference (p

Published
2019
Full Text
View/download PDF

30. Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells

Author

Valarmathy Murugaiah, Chiara Agostinis, Praveen M. Varghese, Beatrice Belmonte, Salvatore Vieni, Fanan A. Alaql, Salman H. Alrokayan, Haseeb A. Khan, Anuvinder Kaur, Terry Roberts, Taruna Madan, Roberta Bulla, and Uday Kishore

Subjects
innate immunity, surfactant protein D, immune surveillance, breast cancer, hyaluronic acid, Immunologic diseases. Allergy, RC581-607
Abstract

Human surfactant protein D (SP-D) belongs to the family of collectins that is composed of a characteristic amino-terminal collagenous region and a carboxy-terminal C-type lectin domain. Being present at the mucosal surfaces, SP-D acts as a potent innate immune molecule and offers protection against non-self and altered self, such as pathogens, allergens, and tumor. Here, we examined the effect of a recombinant fragment of human SP-D (rfhSP-D) on a range of breast cancer lines. Breast cancer has four molecular subtypes characterized by varied expressions of estrogen (ER), progesterone (PR), and epidermal growth factor (EGF) receptors (HER2). The cell viability of HER2-overexpressing (SKBR3) and triple-positive (BT474) breast cancer cell lines [but not of a triple-negative cell line (BT20)] was reduced following rfhSP-D treatment at 24 h. Upregulation of p21/p27 cell cycle inhibitors and p53 phosphorylation (Ser15) in rfhSP-D-treated BT474 and SKBR3 cell lines signified G2/M cell cycle arrest. Cleaved caspases 9 and 3 were detected in rfhSP-D-treated BT474 and SKBR3 cells, suggesting an involvement of the intrinsic apoptosis pathway. However, rfhSP-D-induced apoptosis was nullified in the presence of hyaluronic acid (HA) whose increased level in breast tumor microenvironment is associated with malignant tumor progression and invasion. rfhSP-D bound to solid-phase HA and promoted tumor cell proliferation. rfhSP-D-treated SKBR3 cells in the presence of HA showed decreased transcriptional levels of p53 when compared to cells treated with rfhSP-D only. Thus, HA appears to negate the anti-tumorigenic properties of rfhSP-D against HER2-overexpressing and triple-positive breast cancer cells.

Published
2020
Full Text
View/download PDF

33. PERCEPCIÓN DE RIESGO DE INFECCIÓN POR HIV Y CONOCIMIENTO SOBRE USO DE ANTIRRETROVIRALES EN PREVENCIÓN.

Author

Warley, Eduardo M, Heine, Norma, Garnica, Pablo, Rojas, Federico, Castañeda, Byron, Vilariño, Ainoha, Saboundji, Melisa, Vieni, María Inés, Mores, Sonia, and Tavella, Silvina

Abstract

Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024

36. Gender Differences in Radiation Dose From Nuclear Cardiology Studies Across the World: Findings From the INCAPS Registry

Author

Einstein, A.J., Pascual, T.N.B., Paez, D., Dondi, M., Better, N., Bouyoucef, S.E., Karthikeyan, G., Kashyap, R., Lele, V., Magboo, V.P.C., Mahmarian, J.J., Meeks, J.B., Mercuri, M., Mut, F., Rehani, M.M., Vitola, J.V., Alexanderson, E., Allam, A., Al-Mallah, M.H., Bom, H., Flotats, A., Jerome, S., Kaufmann, P.A., Luxenburg, O., Mahmarian, J., Shaw, L.J., Underwood, S.R., Vitola, J., Amouri, W., Essabbah, H., Gassama, S.S., Makhdomi, K.B., El Mustapha, G.I.E., El Ouchdi, N., Qaïs, N., Soni, N., Vangu, W., Abazid, R.M., Adams, B., Agarwal, V., Alfeeli, M.A., Alnafisi, N., Bernabe, L., Bural, G.G., Chaiwatanarat, T., Chandraguptha, J.M., Cheon, G.J., Cho, I., Dogan, A.S., Eftekhari, M., Frenkel, A., Garty, I., George, S., Geramifar, P., Golan, H., Habib, S., Hussain, R., Im, H., Jeon, H.-J., Kalawat, T., Kang, W.J., Keng, F., Klaipetch, A., Kumar, P.G., Lee, J., Lee, W.W., Lim, I., Macaisa, C.M.M., Malhotra, G., Mittal, B.R., Mohammad, M.H., Mohan, P., Mulyanto, I.D., Nariman, D., Nayak, U.N., Niaz, K., Nikolov, G., Obaldo, J.M., Ozturk, E., Park, J.M., Park, S., Patel, C.D., Phuong, H.K., Quinon, A.P., Rajini, T.R., Saengsuda, Y., Santiago, J., Sayman, H.B., Shinto, A.S., Sivasubramaniyan, V., Son, M.H., Sudhakar, P., Syed, G.M.S., Tamaki, N., Thamnirat, K., Thientunyakit, T., Thongmak, S., Velasco, D.N., Verma, A., Vutrapongwatana, U., Wang, Y., Won, K.S., Yao, Z., Yingsa-nga, T., Yudistiro, R., Yue, K.T., Zafrir, N., Adrian, S.C., Agostini, D., Aguadé, S., Armitage, G., Backlund, M., Backman, M., Baker, M., Balducci, M.T., Bavelaar, C., Berovic, M., Bertagna, F., Beuchel, R., Biggi, A., Bisi, G., Bonini, R., Bradley, A., Brudin, L., Bruno, I., Busnardo, E., Casoni, R., Choudhri, A., Cittanti, C., Clauss, R., Costa, D.C., Costa, M., Dixon, K., Dziuk, M., Egelic, N., Eriksson, I., Fagioli, G., de Faria, D.B., Florimonte, L., Francini, A., French, M., Gallagher, E., Garai, I., Geatti, O., Genovesi, D., Gianolli, L., Gimelli, A., del Giudice, E., Halliwell, S., Hansson, M.J., Harrison, C., Homans, F., Horton, F., Jędrzejuk, D., Jogi, J., Johansen, A., Johansson, H., Kalnina, M., Kaminek, M., Kiss, A., Kobylecka, M., Kostkiewicz, M., Kropp, J., Kullenberg, R., Lahoutte, T., Lang, O., Larsson, Y.H., Lázár, M., Leccisotti, L., Leners, N., Lindner, O., Lipp, R.W., Maenhout, A., Maffioli, L., Marcassa, C., Martins, B., Marzullo, P., Medolago, G., Mendiguchía, C.G., Mirzaei, S., Mori, M., Nardi, B., Nazarenko, S., Nikoletic, K., Oleksa, R., Parviainen, T., Patrina, J., Peace, R., Pirich, C., Piwowarska-Bilska, H., Popa, S., Prakash, V., Pubul, V., Puklavec, L., Rac, S., Ratniece, M., Rogan, S.A., Romeo, A., Rossi, M., Ruiz, D., Sabharwal, N., Salobir, B.G., Santos, A.I., Saranovic, S., Sarkozi, A., Schneider, R.P., Sciagra, R., Scotti, S., Servini, Z., Setti, L.R., Starck, S.-Å., Vajauskas, D., Veselý, J., Vieni, A., Vignati, A., Vito, I.M., Weiss, K., Wild, D., Zdraveska-Kochovska, M., Agüro, R.N., Alvarado, N., Barral, C.M., Beretta, M., Berrocal, I., Batista Cuellar, J.F., Cabral Chang, T.-M., Cabrera Rodríguez, L.O., Canessa, J., Castro Mora, G., Claudia, A.C., Clavelo, G.F., Cruz Júnior, A.F., Faccio, F.F., Fernández, K.M., Gomez Garibo, J.R., Gonzalez, U., González E., P., Guzzo, M.A., Jofre, J., Kapitán, M., Kempfer, G., Lopez, J.L., Massardo V., T., Medeiros Colaco, I., Mesquita, C.T., Montecinos, M., Neubauer, S., Pabon, L.M., Puente, A., Rochela Vazquez, L.M., Serna Macias, J.A., Silva Pino, A.G., Tártari Huber, F.Z., Tovar, A.P., Vargas, L., Wiefels, C., Aljizeeri, A., Alvarez, R.J., Barger, D., Beardwood, W., Behrens, J., Brann, L., Brown, D., Carr, H., Churchwell, K., Comingore, G.A., Corbett, J., Costello, M., Cruz, F., Depinet, T., Dorbala, S., Earles, M., Esteves, F.P., Etherton, E., Fanning, R.J., Jr., Fornace, J., Franks, L., Gewirtz, H., Gulanchyn, K., Hannah, C.-L., Hays, J., Hendrickson, J., Hester, J., Holmes, K., Johnson, A., Jopek, C., Lewin, H., Lyons, J., Manley, C., Meden, J., Moore, S., Moore, W.H., Murthy, V., Nace, R., Neely, D., Nelson, L., Niedermaier, O., Rice, D., Rigs, R., Schiffer, K., Schockling, E., Schultz, T., Schumacker, T., Sheesley, B., Sheikh, A., Siegel, B., Slim, A.M., Smith, J., Szulc, M., Tanskersley, N., Tilkemeier, P., Valdez, G.D., Vrooman, R., Wawrowicz, D., Winchester, D.E., Alcheikh, A., Allen, B., Atkins, E., Bevan, J., Bonomini, C., Christiansen, J., Clack, L., Craig, E., Dixson, H., Duncan, I., Fredericks, S., Gales, S., Hampson, R., Hanley, T., Hartcher, K., Hassall, J., Kelley, B., Kelly, S., Kidd, T., de Kort, T., Larcos, G., Macdonald, W., McGrath, C., Murdoch, E., O'Malley, S., O'Rourke, M., Pack, M., Pearce, R., Praehofer, R., Ramsay, S., Scarlett, L., Smidt, K., Souvannavong, F., Taubman, K., Taylor, G., Tse, K., Unger, S., Weale, J., Shi, Lynn, Dorbala, Sharmila, Paez, Diana, Shaw, Leslee J., Zukotynski, Katherine A., Pascual, Thomas N.B., Karthikeyan, Ganesan, Vitola, João V., Better, Nathan, Bokhari, Nadia, Rehani, Madan M., Kashyap, Ravi, Dondi, Maurizio, Mercuri, Mathew, and Einstein, Andrew J.

Published
2016
Full Text
View/download PDF

37. Implant-Based Breast Reconstruction after Risk-Reducing Mastectomy in BRCA Mutation Carriers: A Single-Center Retrospective Study

Author

Cordova, Emanuele Cammarata, Francesca Toia, Matteo Rossi, Calogero Cipolla, Salvatore Vieni, Antonino Speciale, and Adriana

Subjects
breast cancer, BRCA mutation, risk-reducing mastectomy, breast reconstruction, direct-to-implant breast reconstruction, prepectoral breast reconstruction, acellular dermal matrix
Abstract

Women with BRCA gene mutations have a higher lifetime risk of developing breast cancer. Furthermore, cancer is usually diagnosed at a younger age compared to the wild-type counterpart. Strategies for risk management include intensive surveillance or risk-reducing mastectomy. The latter provides a significant reduction of the risk of developing breast cancer, simultaneously ensuring a natural breast appearance due to the preservation of the skin envelope and the nipple-areola complex. Implant-based breast reconstruction is the most common technique after risk-reducing surgery and can be achieved with either a submuscular or a prepectoral approach, in one or multiple stages. This study analyzes the outcomes of the different reconstructive techniques through a retrospective review on 46 breasts of a consecutive, single-center case series. Data analysis was carried out with EpiInfo version 7.2. Results of this study show no significant differences in postoperative complications between two-stage tissue expander/implant reconstruction and direct-to-implant (DTI) reconstruction, with DTI having superior aesthetic outcomes, especially in the prepectoral subgroup. In our experience, the DTI prepectoral approach has proven to be a safe and less time-consuming alternative to the submuscular two-stage technique, providing a pleasant reconstructed breast and overcoming the drawbacks of subpectoral implant placement.

Published
2023
Full Text
View/download PDF

38. Diagnostic performance of 2D-shear wave elastography in the diagnosis of breast cancer: a clinical appraisal of cutoff values

Author

Tommaso Vincenzo Bartolotta, Alessia Angela Maria Orlando, Mariangela Dimarco, Calogero Zarcaro, Fabiola Ferraro, Alessandra Cirino, Domenica Matranga, Salvatore Vieni, Daniela Cabibi, Bartolotta, Tommaso Vincenzo, Orlando, Alessia Angela Maria, Dimarco, Mariangela, Zarcaro, Calogero, Ferraro, Fabiola, Cirino, Alessandra, Matranga, Domenica, Vieni, Salvatore, and Cabibi, Daniela

Subjects
Adult, Aged, 80 and over, Reproducibility of Results, Breast Neoplasms, General Medicine, Middle Aged, Sensitivity and Specificity, Diagnosis, Differential, Young Adult, Elasticity imaging techniques, Shear wave imaging, Humans, Female, Radiology, Nuclear Medicine and imaging, Ultrasonography, Mammary, Breast, Settore MED/36 - Diagnostica Per Immagini E Radioterapia, Aged, Ultrasonography
Abstract

Purpose To assess the role of 2D-shear wave elastography (2D-SWE) in differentiating benign from malignant focal breast lesions (FBLs), providing new vendor-specific cutoff values. Methods 158 FBLs (size: 3.5-50 mm) detected in 151 women (age: 21-87 years) were prospectively evaluated by means 2D-SWE. For each lesion, an expert radiologist assessed US BI-RADS category and calculated the following four 2D-SWE parameters: (1) elasticity maximum (E-max); (2) mean elasticity (E-mean); (3) minimum elasticity (E-min); (4) elasticity ratio (E-ratio). US-guided core-biopsy was considered as standard of reference for all the FBLs classified as BI-RADS 4 or 5. For each 2D-SWE parameter, the optimal cutoff value for a diagnostic test was calculated using the Youden method. Diagnostic performance of the US BI-RADS and 2D-SWE parameters was calculated accordingly. Results 83/158 (52.5%) FBLs were benign and 75/158 (47.5%) were malignant. Statistically significant higher stiffness values were observed in malignant FBLs for all 2D-SWE parameters than in benign ones (p < 0.001). 2D-SWE cutoff values were 82.6 kPa, 66.0 kPa and 53.6 kPa, respectively, for E-max, E-mean, E-min and 330.8% for E-ratio. The 2D-SWE parameter showing the best diagnostic accuracy was E-max (85.44%). Considering US BI-RADS 3 (n = 60) and 4a (n = 32) FBLs, E-max and E-mean showed the best diagnostic accuracy (85.87% for both), without a statistically significant decrease in sensitivity (p = 0.7003 and p = 1, respectively). Conclusion Our study provides new vendor-specific cutoff values for 2D-SWE, suggesting its possible clinical use in the adjunctive assessment of category US-BI-RADS 3 and 4a breast masses.

Published
2022

39. Potential Activity of Albino Grifola frondosa Mushroom Extract against Biofilm of Meticillin-Resistant Staphylococcus aureus

Author

Teresa Fasciana, Maria Letizia Gargano, Nicola Serra, Elena Galia, Ignazio Arrigo, Maria Rita Tricoli, Orazia Diquattro, Giuseppa Graceffa, Salvatore Vieni, Giuseppe Venturella, and Anna Giammanco

Subjects
Grifola frondosa, biofilm, Staphylococcus aureus, activities, Biology (General), QH301-705.5
Abstract

Mushroom extracts are a rich source of natural compounds with antimicrobial properties, which are able to prevent, to some extent, the growth of foodborne pathogens. The aim of this study was to investigate the potential of extracts from albino Grifola frondosa (GF), commonly known as maitake, to inhibit the growth of some bacteria and the biofilm production by Staphylococcus aureus. We obtained not only a significant reduction of OD score between biofilm and biofilm plus albino G. frondosa extract group, but also a reduction of category of biofilm. In addition, we observed a significant presence of isolates with strong category for the biofilm group and a significant presence of isolates with absent category for the biofilm plus albino G. frondosa extract group. These results confirm that the use of albino G. frondosa extract reduces in significant way the presence of biofilm. Our results suggest and confirm that albino G. frondosa extracts could be employed as functional food and could be used as a natural additive for food process control and food safety.

Published
2021
Full Text
View/download PDF

40. The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis

Author

Antonio Galvano, Luisa Castellana, Valerio Gristina, Maria La Mantia, Lavinia Insalaco, Nadia Barraco, Alessandro Perez, Sofia Cutaia, Valentina Calò, Tancredi Didier Bazan Russo, Edoardo Francini, Lorena Incorvaia, Mario Giuseppe Mirisola, Salvatore Vieni, Christian Rolfo, Viviana Bazan, Antonio Russo, Galvano, Antonio, Castellana, Luisa, Gristina, Valerio, La Mantia, Maria, Insalaco, Lavinia, Barraco, Nadia, Perez, Alessandro, Cutaia, Sofia, Calò, Valentina, Bazan Russo, Tancredi Didier, Francini, Edoardo, Incorvaia, Lorena, Mirisola, Mario Giuseppe, Vieni, Salvatore, Rolfo, Christian, Bazan, Viviana, and Russo, Antonio

Subjects
meta-analysis, breast cancer, Oncology, diagnostic accuracy, PIK3CA, ctDNA
Abstract

Background: The circulating tumor DNA (ctDNA) diagnostic accuracy for detecting phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations in breast cancer (BC) is under discussion. We aimed to compare plasma and tissue PIK3CA alterations, encompassing factors that could affect the results. Methods: Two reviewers selected studies from different databases until December 2020. We considered BC patients with matched tumor tissue and plasma ctDNA. We performed meta-regression and subgroup analyses to explore sources of heterogeneity concerning tumor burden, diagnostic technique, sample size, sampling time, biological subtype, and hotspot mutation. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the related area under the curve (AUC) were elaborated for the overall population and each subgroup. Results: The pooled analysis was carried out on 25 cohorts for a total of 1966 patients. The overall ctDNA sensitivity and specificity were 0.73 (95% CI: 0.70–0.77) and 0.87 (95% CI: 0.85–0.89). The AUC was 0.93. Pooled concordance, negative predictive value and positive predictive value values were 0.87 (95% CI: 0.82–0.92), 0.86 (95% CI: 0.81–0.90), and 0.89 (95% CI: 0.81–0.95) with pooled PLR, NLR, and DOR of 7.94 (95% CI: 4.90–12.86), 0.33 (95% CI: 0.25–0.45), and 33.41 (95% CI: 17.23–64.79), respectively. The pooled results consistently favored next-generation sequencing (NGS)- over polymerase chain reaction-based methodologies. The best ctDNA performance in terms of sensitivity, specificity, and AUC (0.85, 0.99, and 0.94, respectively) was observed in the low-time sampling subgroup (⩽18 days between tissue and plasma collection). Meta-regression and subgroup analyses highlighted sampling time as a possible major cause of heterogeneity. Conclusions: These findings reliably estimate the high ctDNA accuracy for the detection of PIK3CA mutations. A ctDNA-first approach for the assessment of PIK3CA mutational status by NGS may accurately replace tissue tumor sampling, representing the preferable strategy at diagnosis of metastatic BC in patients who present with visceral involvement and at least two metastatic lesions, primarily given low clinical compliance or inaccessible metastatic sites.

Published
2022

41. Helicobacter pylori and Epstein–Barr Virus Co-Infection in Gastric Disease: What Is the Correlation with p53 Mutation, Genes Methylation and Microsatellite Instability in a Cohort of Sicilian Population?

Author

Giammanco, Anna, primary, Anzalone, Rita, additional, Serra, Nicola, additional, Graceffa, Giuseppa, additional, Vieni, Salvatore, additional, Scibetta, Nunzia, additional, Rea, Teresa, additional, Capra, Giuseppina, additional, and Fasciana, Teresa, additional

Published
2023
Full Text
View/download PDF

42. Supplementary Figure S5 from IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Gaggianesi, Miriam, primary, Turdo, Alice, primary, Chinnici, Aurora, primary, Lipari, Elisa, primary, Apuzzo, Tiziana, primary, Benfante, Antonina, primary, Sperduti, Isabella, primary, Di Franco, Simone, primary, Meraviglia, Serena, primary, Lo Presti, Elena, primary, Dieli, Francesco, primary, Caputo, Valentina, primary, Militello, Gabriella, primary, Vieni, Salvatore, primary, Stassi, Giorgio, primary, and Todaro, Matilde, primary

Published
2023
Full Text
View/download PDF

43. Data from IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Gaggianesi, Miriam, primary, Turdo, Alice, primary, Chinnici, Aurora, primary, Lipari, Elisa, primary, Apuzzo, Tiziana, primary, Benfante, Antonina, primary, Sperduti, Isabella, primary, Di Franco, Simone, primary, Meraviglia, Serena, primary, Lo Presti, Elena, primary, Dieli, Francesco, primary, Caputo, Valentina, primary, Militello, Gabriella, primary, Vieni, Salvatore, primary, Stassi, Giorgio, primary, and Todaro, Matilde, primary

Published
2023
Full Text
View/download PDF

44. Supplementary information from IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Gaggianesi, Miriam, primary, Turdo, Alice, primary, Chinnici, Aurora, primary, Lipari, Elisa, primary, Apuzzo, Tiziana, primary, Benfante, Antonina, primary, Sperduti, Isabella, primary, Di Franco, Simone, primary, Meraviglia, Serena, primary, Lo Presti, Elena, primary, Dieli, Francesco, primary, Caputo, Valentina, primary, Militello, Gabriella, primary, Vieni, Salvatore, primary, Stassi, Giorgio, primary, and Todaro, Matilde, primary

Published
2023
Full Text
View/download PDF

45. An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics

Author

Benfante, Viviana, primary, Stefano, Alessandro, additional, Ali, Muhammad, additional, Laudicella, Riccardo, additional, Arancio, Walter, additional, Cucchiara, Antonino, additional, Caruso, Fabio, additional, Cammarata, Francesco Paolo, additional, Coronnello, Claudia, additional, Russo, Giorgio, additional, Miele, Monica, additional, Vieni, Alessandra, additional, Tuttolomondo, Antonino, additional, Yezzi, Anthony, additional, and Comelli, Albert, additional

Published
2023
Full Text
View/download PDF

46. Litter Decomposition Rate of Karst Ecosystem at Gunung Cibodas, Ciampea Bogor Indonesia

Author

Sethyo Vieni Sari, Ibnul Qayim, and Iwan Hilwan

Subjects
C/N ratio, decomposition, Gunung Cibodas, karst ecosystem, litter, Biology (General), QH301-705.5
Abstract

The study aims to know the productivity of litter and litter decomposition rate in karst ecosystem. This study was conducted on three altitude of 200 meter above sea level (masl), 250 masl and 300 masl in karst ecosystem at Gunung Cibodas, Ciampea, Bogor. Litter productivity measurement performed using litter-trap method and litter-bag method was used to know the rate of decomposition. Litter productivity measurement results showed that the highest total of litter productivity measurement results was on altitude of 200 masl (90.452 tons/ha/year) and the lowest was on altitude of 300 masl (25.440 tons/ha/year). The litter productivity of leaves (81.425 ton/ha/year) showed the highest result than twigs (16.839 ton/ha/year), as well as flowers and fruits (27.839 ton/ha/year). The rate of decomposition was influenced by rainfall. The decomposition rate and the decrease of litter dry weight on altitude of 250 masl was faster than on the altitude of 200 masl and 300 masl. The dry weight was positively correlated to the rate of decomposition. The lower of dry weight would affect the rate of decomposition become slower. The average of litter C/N ratio were ranged from 28.024%--28.716% and categorized as moderate (>25). The finding indicate that the rate of decomposition in karst ecosystem at Gunung Cibodas was slow and based on C/N ratio of litter showed the mineralization process was also slow.

Published
2016
Full Text
View/download PDF

47. Data from IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Matilde Todaro, Giorgio Stassi, Salvatore Vieni, Gabriella Militello, Valentina Caputo, Francesco Dieli, Elena Lo Presti, Serena Meraviglia, Simone Di Franco, Isabella Sperduti, Antonina Benfante, Tiziana Apuzzo, Elisa Lipari, Aurora Chinnici, Alice Turdo, and Miriam Gaggianesi

Abstract

The tumor microenvironment supplies proinflammatory cytokines favoring a permissive milieu for cancer cell growth and invasive behavior. Here we show how breast cancer progression is facilitated by IL4 secreted by adipose tissue and estrogen receptor–positive and triple-negative breast cancer cell types. Blocking autocrine and paracrine IL4 signaling with the IL4Rα antagonist IL4DM compromised breast cancer cell proliferation, invasion, and tumor growth by downregulating MAPK pathway activity. IL4DM reduced numbers of CD44+/CD24− cancer stem-like cells and elevated expression of the dual specificity phosphatase DUSP4 by inhibiting NF-κB. Enforced expression of DUSP4 drove conversion of metastatic cells to nonmetastatic cells. Mechanistically, RNAi-mediated attenuation of DUSP4 activated the ERK and p38 MAPK pathways, increased stem-like properties, and spawned metastatic capacity. Targeting IL4 signaling sensitized breast cancer cells to anticancer therapy and strengthened immune responses by enhancing the number of IFNγ-positive CTLs. Our results showed the role of IL4 in promoting breast cancer aggressiveness and how its targeting may improve the efficacy of current therapies. Cancer Res; 77(12); 3268–79. ©2017 AACR.

Published
2023
Full Text
View/download PDF

48. Supplementary Figure S5 from IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Matilde Todaro, Giorgio Stassi, Salvatore Vieni, Gabriella Militello, Valentina Caputo, Francesco Dieli, Elena Lo Presti, Serena Meraviglia, Simone Di Franco, Isabella Sperduti, Antonina Benfante, Tiziana Apuzzo, Elisa Lipari, Aurora Chinnici, Alice Turdo, and Miriam Gaggianesi

Abstract

IL-4 contributes to the pro-tumorigenic breast cancer milieu

Published
2023
Full Text
View/download PDF

49. Supplementary information from IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

Author

Matilde Todaro, Giorgio Stassi, Salvatore Vieni, Gabriella Militello, Valentina Caputo, Francesco Dieli, Elena Lo Presti, Serena Meraviglia, Simone Di Franco, Isabella Sperduti, Antonina Benfante, Tiziana Apuzzo, Elisa Lipari, Aurora Chinnici, Alice Turdo, and Miriam Gaggianesi

Abstract

Supplementary Material and Methods and Supplementary Figure Legends

Published
2023
Full Text
View/download PDF

50. Navigating the liquid biopsy Minimal Residual Disease (MRD) in Non-Small Cell Lung Cancer: Making the Invisible Visible

Author

Gristina, Valerio, La Mantia, Maria, Peri, Marta, Iacono, Federica, Barraco, Nadia, Perez, Alessandro, Viscardi, Giuseppe, Cutaia, Sofia, Russo, Tancredi Didier Bazan, Anwar, Zubair, Incorvaia, Lorena, Fulfaro, Fabio, Vieni, Salvatore, Pantuso, Gianni, Graceffa, Giuseppa, Russo, Antonio, Galvano, Antonio, Bazan, Viviana, Gristina, Valerio, La Mantia, Maria, Peri, Marta, Iacono, Federica, Barraco, Nadia, Perez, Alessandro, Viscardi, Giuseppe, Cutaia, Sofia, Russo, Tancredi Didier Bazan, Anwar, Zubair, Incorvaia, Lorena, Fulfaro, Fabio, Vieni, Salvatore, Pantuso, Gianni, Graceffa, Giuseppa, Russo, Antonio, Galvano, Antonio, and Bazan, Viviana

Subjects
Liquid biopsy, Non-small cell lung cancer, Oncology, Minimal residual disease, NGS, Hematology, Cancer diagnostics
Abstract

Liquid biopsy has gained increasing interest in the growing era of precision medicine as minimally invasive technique. Recent findings demonstrated that detecting minimal or molecular residual disease (MRD) in NSCLC is a challenging matter of debate that need multidisciplinary competencies, avoiding the overtreatment risk along with achieving a significant survival improvement. This review aims to provide practical consideration for solving data interpretation questions about MRD in NSCLC thanks to the close cooperation between biologists and oncology clinicians. We discussed with a translational approach the critical point of view from benchside, bedside and bunchside to facilitate the future applicability of liquid biopsy in this setting. Herein, we defined the clinical significance of MRD, focusing on relevant practical consideration about advantages and disadvantages, speculating on future clinical trial design and standardization of MRD technology.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results